Abstracts

DENDRITIC CELL VACCINATION AGAINST HIV ALTERS NK CELL FREQUENCY AND PHENOTYPE

Natural killer (NK) cells play an essential role in the antiviral immune response. Moreover, dendritic cell (DC)-NK crosstalk has been described extensively. However, their role in dendritic cell (DC)-based therapeutic vaccination against HIV remains understudied. Therefore, we aimed to investigate whether DC-based vaccination affects NK cell frequency and phenotype by analysing samples from a previously…

EX VIVO ASSAY PREDICTS HIV-1 SUPPRESSION BY bNAbs INFUSED IN A PHASE I CLINICAL TRIAL

Broadly neutralizing antibodies (bNAbs) target conserved regions of the HIV-1 envelope and show potential as complementary immunotherapy to combination anti-retroviral therapies (cART) for HIV-1 treatment. However, infusion of a single bNAb in viremic individuals results in selection for escape variants that are likely part of the individuals viral quasispecies. To better predict the potential for…

ChAdOx1 nCoV-19 VACCINATION IN PWH: IMMUNE RESPONSES TO SARS-CoV-2, VOCs, AND HCoVs

People living with HIV (PWH) may represent a high-risk group for adverse clinical outcomes from SARS-CoV-2. The duration of protection from SARS-CoV-2 and emerging variants of concern (VOC) infection in PWH following vaccination is unclear. Furthermore, the role of pre-existing SARS-CoV-2 immune responses, likely acquired from prior exposure to circulating human coronaviruses (HCoVs), on vaccine-mediated…

STRAIN-SPECIFIC SEROLOGICAL RESPONSE FOLLOWING SARS-CoV-2 VOC INFECTION

The emergence of new SARS-CoV-2 variants raises concerns whether pre-existing artificial (vaccine-induced) and natural immunity from prior COVID-19 prevents re-infections. Here, we investigated the differences in primary humoral immune response following SARS-CoV-2 variants of concern (VOCs) infection and aimed to identify the key mutations involved in these differences. Patients with primary PCR-proven SARS-CoV-2 infection with…

ESTABLISHMENT OF AN ANTI-RBD THRESHOLD THAT PREDICTS ROBUST NEUTRALIZING ACTIVITY

Although presence of SARS-CoV-2 neutralising antibodies can provide protection against development of COVID-19, how reflective circulating anti-SARS-CoV-2 antibody levels are of underlying neutralising capacity, and whether a threshold exists to predict sufficient neutralising capacity remains unclear. In plasma from individuals with PCR-confirmed COVID-19 recruited to the All Ireland Infectious Diseases Cohort Study, we measured IgG…

HIGHER CORONAVIRUS ANTIBODY RESPONSES PREPANDEMIC IN AFRICA THAN IN THAILAND

COVID-19 clinical manifestations range from asymptomatic to severe disease. Prior immune responses to human coronaviruses may affect individual responses to SARS-CoV-2. We surveyed coronavirus responses pre-pandemic in individuals from Kenya, Nigeria, Tanzania, Uganda and Thailand; 81% were people living with HIV. Specimens were screened for SARS-CoV-2 Spike S2 subunit IgG responses. Selected samples were tested…

IMMUNOAGONIST CONVERTS CMV-SPECIFIC T CELLS INTO MORE POTENT HIV-SPECIFIC CAR-T CELLS

We developed novel immunoagonists (synTacs) to selectively activate and expand virus-specific CD8+ T cells in vitro and in vivo. SynTacs consist of dimeric Fc-domain scaffolds linking CD28-specific agonists to HLA-A2 MHC molecules covalently-tethered to a virus-derived peptide enabling delivery of TCR-specific and costimulatory signals to antigen-specific T cells. We hypothesized that synTac-activation of virus-specific effector-memory…